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Abstract
Background: Having observed a tendency towards femoral overgrowth (FO) of the affected limb in children with
atrophic-type congenital pseudarthrosis of the tibia (CPT), we aimed to identify the incidence of, contributors to,
and patterns of FO among such children.
Methods: We retrospectively evaluated 55 children with CPT, 22 with prepseudarthrosis and 33 with atrophic-type
CPT from 1989 to 2012. FO was defined as an affected femoral segment ≥10 mm longer than the contralateral
segment. We investigated FO incidences in prepseudarthrosis versus atrophic-type CPT. Sex, laterality, coexistence
of neurofibromatosis type 1, development of frank pseudarthrosis, extent of tibial shortening, shortening in foot
height, deformity severity, distraction osteogenesis (DO) treatment, refracture, increased femoral neck-shaft angle,
tibiofemoral angle, and ankle valgus angle were investigated to identify potential contributors to FO. Patterns of FO
were also determined.
Results: At initial presentation, 11 patients exhibited a mean of 13 mm (10–23) of FO. However, the nature of FO
changed over time during the follow-up period (mean, 10.8 years; range, 4.3–19.3). At the last follow-up, 14 patients
presented with a mean of 12 mm (10–18) of FO. With the exception of one patient, all patients with FO presented
with atrophic-type CPT. Frank pseudarthrosis, DO treatment, and increased femoral neck-shaft angle were
significantly associated with FO (p = 0.016, p = 0.001, and p = 0.005, respectively). Diverse patterns of FO were
observed.
Conclusions: FO of the affected limb is frequently encountered in patients with atrophic-type CPT. A
compensatory response to frank pseudarthrosis, DO treatment, and neurofibromatosis may play a role in the diverse
patterns of FO.
Keywords: Congenital pseudarthrosis of the tibia, Femoral overgrowth, Distraction osteogenesis, Neurofibromatosis
Background
The vast majority of patients with congenital pseudar-
throsis of the tibia (CPT) present with a dysplastic tibia
with an anterolateral bow at birth [1, 2]. In a few cases,
this condition has a benign course of nondysplastic an-
terolateral bowing; however, most individuals with this
condition undergo dysplastic changes, including failure
of tubulation and a widened medullary canal, or cystic
prefracture or canal enlargement from a prior fracture
[3, 4]. This prefracture status is called ‘prepseudarthro-
sis’. Once a fracture occurs, there is little tendency for
the lesion to heal spontaneously, and frank
pseudarthrosis with atrophic ends, the so-called ‘atro-
phic-type CPT’, usually results [2]. Therefore, it may be
more appropriate to describe this entire phenomenon as
anterolateral bowing of the tibia with congenital dyspla-
sia rather than CPT [1–3, 5] because it is obviously a
heterogeneous entity with different prognoses [1].
The treatment of atrophic-type CPT is challenging.
Despite marked improvement in the primary healing
rate as a result of modern treatment methods, the re-
sidual problems are often perplexing and demanding [2,
6, 7]. We have used the Ilizarov technique for atrophic-
type CPT since the late 1980s. This technique enables a
multi-targeted approach to osteosynthesis, axial realign-
ment, ankle mortise stabilization, and limb length
equalization. Interestingly, we have observed a tendency
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toward femoral overgrowth (FO) of the affected limb
in atrophic-type CPT compared with prepseudarthro-
sis. In the literature, only two previous reports briefly
addressed FO of the affected limb in CPT, especially
in atrophic-type CPT [5, 8]. It is the intention of this
study to investigate the incidence of FO in patients
with atrophic-type CPT versus prepseudarthrosis. We
hypothesized that patients with atrophic-type CPT
would have a higher incidence of FO compared with
those with prepseudarthrosis. We also attempted to
identify potential contributors to FO and to deter-
mine various patterns of FO.
Methods
This study is a retrospective review of children with
CPT who were treated at our institution from 1989 to
2012. Patients diagnosed with CPT and followed until
preadolescence or adolescence were included; patients
who were at least 10 years of age at initial assessment,
had incomplete medical records and radiographs with a
relatively short follow-up, and/or had generalized hemi-
hypertrophy of the lower limb caused by neurofibroma-
tosis were excluded. A total of 55 CPT patients (26 boys
and 29 girls) who were unilaterally affected (on the right
and left sides for 24 and 31 patients, respectively) were
enrolled in this study. Forty-nine patients began their
treatment at our institution, and the remaining six were
referred to us after the failure of previous osteosynthesis
attempts. At initial presentation, 16 patients were classi-
fied as Crawford Type I; 6 as Crawford Type II; 3 as
Crawford Type III; and 30 as Crawford Type IV [9].
Thirty-nine patients had neurofibromatosis type 1
(NF1); the remaining sixteen did not. The mean age at
initial presentation was 2.8 years (0.1–7.3), and the pa-
tients were followed for 10.8 years (4.3–19.3). Twenty-
two patients remained in the prepseudarthrotic stage
during the follow-up period; in contrast, 33 patients ex-
hibited atrophic-type CPT. Table 1 summarizes the char-
acteristics of the patients with prepseudarthrosis versus
atrophic-type CPT.
Among the 22 patients with prepseudarthrosis, two
patients underwent prophylactic bypass grafting, 10 pa-
tients wore an ankle-foot orthosis or a short leg cast,
and the remaining 10 patients were simply observed
without any treatment. In contrast, all 33 of the patients
with atrophic-type CPT underwent the authors’ fibular
status-based Ilizarov treatment [6] for osteosynthesis
alone (n = 9) or for osteosynthesis in addition to distrac-
tion osteogenesis (DO) of the tibia/fibula (n = 24).
Twenty-four patients underwent 31 rounds of DO of the
affected tibia, with three rounds of DO in 2 patients,
two rounds of DO in 3, and one round of DO in 19. The
mean age at surgery was 4.5 years (1.7–7.3).
FO was defined as an affected femoral segment
≥10 mm longer than the contralateral segment based on
a slit scanogram (as described by Bell and Thompson)
[10], whereas a femoral segment length discrepancy of
<10 mm was regarded as non-significant [5]. The inci-
dences of FO in the prepseudarthrosis group and the
atrophic-type CPT group were compared. The nature of
the FO was classified as either FO that was consistent
during follow-up (Type A); FO that was not observed at
the initial presentation but that developed and remained
during follow-up (Type B); FO that was observed at the
initial presentation but that was not apparent during
follow-up (Type C); and FO that developed after the ini-
tial presentation and subsequently resolved (Type D).
To identify potential contributors associated with FO,
we investigated the following variables: sex, laterality, co-
existence of NF1, development of frank pseudarthrosis,
extent of tibial shortening, shortening in foot height, se-
verity of the deformity, DO treatment, refracture after
Ilizarov osteosynthesis, increased femoral neck-shaft
angle, tibiofemoral angle, and ankle valgus angle. Tibial
length of the affected limb was replaced by effective tib-
ial length [11], which was measured from the medial
plateau to the plafond; the extent of tibial shortening
was then measured as the difference between the tibial
lengths of the unaffected and the affected limbs. Short-
ening in foot height was defined as an affected foot
Table 1 Patient characteristics of prepseudarthrosis versus atrophic-type CPT
Variables Prepseudarthrosis Atrophic-type CPT
(n = 22) (n = 33) p-value
Age at initial presentation (years) 3.0 (0.1–4.5) 2.6 (0.1–7.3) 0.595a
Sex (Male: Female) 13 : 9 13 : 20 0.152b
Laterality (Right: Left) 9 : 13 15 : 18 0.739b
Neurofibromatosis type 1 (Presence: Absence) 10 : 12 29 : 4 0.001b
Crawford classification (I: II: III: IV) 16 : 6 : 0 : 0 0 : 0 : 3 : 30 <0.001b
Femoral overgrowth At initial presentation 1 : 21 10 : 23 0.019b
(With: Without) At last follow-up 1 : 21 13 : 20 0.004b
CPT congenital pseudarthrosis of the tibia
aIndependent t-test, bFisher’s exact test
Song et al. BMC Musculoskeletal Disorders  (2016) 17:274 Page 2 of 8
height ≥5 mm shorter than the contralateral foot height;
foot height was measured from the talar dome to the
floor [12]. Deformity severity was determined based on
the length of the atrophic segment, including the pseu-
darthrosis portion, as a percentage of the entire length
of the affected tibia. The femoral neck-shaft angle was
defined as the angle between the axis of the femoral
neck passing through the center of the femoral head and
the axis of the femoral shaft [13], and an increased fem-
oral neck-shaft angle was defined as an increase of ≥10°
in the femoral neck-shaft angle of the affected limb
compared with the contralateral limb. The tibiofemoral
angle was defined as the angle formed by the axis of the
femur and the axis of the tibia [14], whereas the ankle
valgus angle was regarded as the angle between the axis
of the tibial shaft and the tibial plafond line [15]. We
also examined the effect of an increased femoral neck-
shaft angle on FO. This length-gain effect was calcu-
lated by subtracting the distance between the summit
of the femoral head and the mid-level of the lesser tro-
chanter of the unaffected limb from that of the affected
limb.
We assessed patterns of FO to determine whether
femoral segment length discrepancies for the affected
limb followed any of the developmental patterns of limb
length discrepancy that were previously reported by Sha-
piro [16].
Statistics
We used the independent t-test for continuous vari-
ables and Fisher’s exact test for categorical variables
to compare the characteristics of patients with pre-
pseudarthrosis with those of patients with atrophic-
type CPT. To identify potential contributors associ-
ated with FO, we analyzed numerical variables using
independent t-test, whereas categorical variables were
analyzed using Fisher’s exact test. We then performed
multivariate logistic regression analysis with FO as
the outcome variable; dependent variables were those
with p-values <0.05 on the univariate analysis or
those with clinical significance. Statistical analyses
were performed using SPSS, ver. 21.0 (SPSS, IBM
Corp., Chicago, IL); p-values < 0.05 were regarded as
statistically significant.
Results
Incidence of femoral overgrowth
At initial presentation, 11 patients exhibited a mean of
13 mm (10–23) of FO. Tibial shortening was 32 mm
(−6–77), and shortening in foot height was 6 mm (6–8).
However, the nature of FO changed over time for certain
patients. At the last follow-up, 14 patients presented
with FO; the average FO was 12 mm (10–18), and the
affected tibia was 9 mm shorter (−18–48) than the
contralateral tibia. Overall, 22 patients exhibited
≥10 mm of FO at least once during the follow-up period.
Six cases were classified as Type A FO; seven as Type B
(Fig. 1); four as Type C (Fig. 2); and four as Type D.
Table 2 summarizes information regarding the 22 pa-
tients with FO at least once.
Contributors associated with femoral overgrowth
Only development of frank pseudarthrosis, extent of
tibial shortening, DO treatment, and increased fem-
oral neck-shaft angle were included in multivariate
logistic regression analysis because the p-values of
each of these parameters were <0.05 on the univariate
analysis (p = 0.004, p = 0.046, p < 0.001, and p = 0.002,
respectively). Frank pseudarthrosis, DO treatment, and
increased femoral neck-shaft angle were significantly asso-
ciated with FO (p = 0.016, p = 0.001, and p = 0.005,
respectively).
The development of frank pseudarthrosis significantly
contributed to FO (odds ratio [OR], 13.650; 95 % confi-
dence interval [CI], 1.632 to 114.191; p = 0.016). Notably,
the incidence of FO was significantly higher in patients
with atrophic-type CPT than in patients with prepseu-
darthrosis; 13 (39.4 %) patients with atrophic-type CPT
exhibited FO at the last follow-up, whereas only one
(4.5 %) patient with prepseudarthrosis exhibited FO
(Table 1).
DO treatment was another significant contributor to
FO (OR, 14.500; 95 % CI, 2.809 to 74.837; p = 0.001).
The per-patient numbers of DO treatments are pre-
sented in Table 2. Patients with Types B and D FO com-
monly underwent only one round of DO: 9 patients
underwent one round of DO, and 1 patient underwent
three rounds. However, most of the patients with Type C
FO underwent more than two rounds of DO: 1 patient
underwent three rounds of DO, 2 patients underwent
two rounds, and 1 patient underwent one round.
An increased femoral neck-shaft angle of the af-
fected limb was also significantly associated with FO
(OR, 7.897; 95 % CI, 1.878 to 33.203; p = 0.005). The
effect of an increased femoral neck-shaft angle on
FO (length gain effect) is presented in Table 2
(range, 0–6 mm). When present, increased femoral
neck-shaft angle of the affected limb exhibited a
consistent trend from the initial presentation (mean,
15°; range, 10–31°) to the last follow-up (mean, 11°;
range, 10–24°) and was not affected by the extent of
tibial/fibular length gain.
Patterns of femoral overgrowth
Patterns of FO were also evaluated for the 22 patients
who exhibited ≥10 mm of FO at least once during the
follow-up period (Table 2). Only one femoral segment
displayed an upward linear slope growth-stimulated
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pattern (modified Shapiro Type 1); three femoral seg-
ments had upward slope-deceleration patterns; six fem-
oral segments had upward slope-plateau patterns; three
femoral segments had upward slope-plateau-upward
slope patterns; and four femoral segments had upward
slope-plateau-downward slope patterns. We were unable
to correlate the patterns of five femoral segments with
Shapiro’s developmental patterns [16].
Discussion
To the best of our knowledge, this is the first report to
systematically investigate the incidence of, contributors
Fig. 1 An example of Type B femoral overgrowth in a 14.6-year-old boy (Patient 13). a No femoral overgrowth of the affected limb was observed
at age 5.5 years. b Femoral overgrowth of the affected limb was initiated during distraction osteogenesis. c Femoral overgrowth persisted until
preadolescence. d The pattern of femoral overgrowth was classified as the upward slope-deceleration pattern (modified Shapiro Type 2) [16]. The
white diamond indicates the point at which the patient underwent distraction osteogenesis
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to, and patterns of FO of the affected limb in CPT. Our
study demonstrates that FO is not infrequently observed
in patients with atrophic-type CPT.
Information about FO of the affected limb in CPT is
rare in the literature. Only two previously published
reports briefly mentioned FO in CPT [5, 8]. Iamaguchi
et al. observed an average of 20 mm (5–50) of FO in
25 % (4/16) of Brazilian patients with atrophic-type CPT
[8]. Horn et al. reported that only a single Norwegian
patient with prepseudarthrosis had 11 mm of FO;
Fig. 2 An example of Type C femoral overgrowth in a 16-year-old girl (Patient 16). a At age seven years, the patient, exhibiting 14 mm of femoral
overgrowth of the affected limb, had failed to achieve union of the tibia via bone transport using the Ilizarov method and was referred to our in-
stitution. b After the patient underwent distraction osteogenesis, the femoral overgrowth resolved. c No significant femoral overgrowth was evi-
dent after the patient reached skeletal maturity. d The pattern of femoral overgrowth did not correlate with any of the subtypes defined by
Shapiro’s classification [16]. The white diamond indicates the point at which the patient underwent distraction osteogenesis
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however, 52 % (10/19) of Norwegian patients with
atrophic-type CPT exhibited a mean of 20 mm (14–29)
of FO [5]. In comparison, our study found that 4.5 % (1/
22) of patients with prepseudarthrosis presented 10 mm
of FO during 9 years of longitudinal follow-up, whereas
39.4 % (13/33) of patients with atrophic-type CPT exhib-
ited an average of 12 mm (10–18) of FO. Based on a
compilation of all of the data from previous reports and
our own study, it is evident that atrophic-type CPT dem-
onstrates a significantly higher incidence of FO com-
pared with prepseudarthrosis.
In previous reports, Iamaguchi et al. [8] and Horn
et al. [5] postulated that the mechanism of FO reflects a
compensatory response. We agree with these authors’
opinion that FO is likely a compensatory response to
marked tibial shortening in patients with atrophic-type
CPT. However, compensation alone cannot explain the
reason(s) why only a fraction of such patients demon-
strate FO at initial presentation or during treatment.
Given that longitudinal long bone growth is affected by
complex mechanisms with multiple factors, e.g., mech-
anical, hormonal, electrochemical, nutritional, genetic,
and other factors [2], the FO observed in patients with
CPT may be a reaction to those multiple influences. Our
study clearly demonstrates that DO treatment coupled
with osteosynthesis for atrophic-type CPT could influ-
ence the development of FO. This finding supports the
notion that hyperemic stimulation after tibial osteotomy
may induce FO of the affected limb, given that regional
blood flow increases 10-fold during the distraction
period and doubles until 17 weeks after the operation
[17, 18]; moreover, blood flow also increases at sites
Table 2 Summary of 22 children who demonstrated femoral overgrowth (FO) of the affected limb during follow-up













Segment length discrepancy (mm) Age
(years)
Segment length discrepancy (mm)
Femur (Length-gain effect)b Tibia Femur (Length-gain effect)b Tibia
1a F 7.3 +10 (0) −9 none 0 16.3 +10 (0) −6 A 3
2a F 1.3 +17 (3) −48 1 16 15.0 +17 (3) −4 A 3
3a F 0.8 +12 (4) −61 1 52 7.7 +10 (3) −13 A 3
4a M 0.8 +10 (6) +2 1 30 10.0 +10 (4) −3 A 3
5a M 1.0 +10 (3) −6 none 0 17.0 +13 (3) −3 A 4
6a M 5.0 +15 (3) −2 1 15 17.3 +10 (3) −22 A unclassifiable
7a M 3.2 +10 (4) −3 1 12 12.0 +10 (2) −13 A 3
8a M 1.0 +7 (3) −30 3 90 16.0 +13 (3) −48 B 4
9a F 0.1 +5 (4) −98 1 53 13.9 +11 (1) −28 B 2
10a M 6.1 0 (2) −6 1 50 20.4 +10 (2) −3 B 1
11a F 0.8 0 (3) −13 1 35 19.1 +12 (3) −19 B 4
12a M 5.3 +6 (4) −10 1 17 17.3 +18 (6) +1 B 2
13a M 5.5 +8 (5) −35 1 15 14.6 +12 (3) −18 B 2
14a F 6.6 +3 (4) −18 1 15 17.6 +15 (3) −28 B 3
15a F 7.1 +23 (3) −48 3 111 16.3 0 (2) −25 C unclassifiable
16a F 7.0 +14 (3) −75 2 102 16.0 +5 (4) −21 C unclassifiable
17a M 1.0 +11 (4) −59 2 76 8.3 +4 (4) +4 C unclassifiable
18a F 0.2 +10 (1) −41 1 33 7.5 0 (1) +6 C unclassifiable
19a M 1.3 +5 (2) −10 1 69 16.0 +7 (4) −3 D 5
20a F 2.9 +3 (4) −90 1 38 16.1 +8 (4) −19 D 5
21a F 3.7 0 (1) −46 1 15 14.1 +2 (2) −21 D 5
22a F 0.3 +2 (1) −10 none 0 13.8 +5 (0) −12 D 5
DO, distraction osteogenesis
Data represent the discrepancy of the femur and tibia (+, longer in the affected limb; −, shorter in the affected limb)
aPatient 1 was the only patient with prepseudarthrosis; all of the other patients presented with atrophic-type CPT
bLength-gain effect was defined as the effect of an increased femoral neck-shaft angle on FO. The length-gain effect was calculated by subtracting the distance
between the summit of the femoral head and the mid-level of the lesser trochanter of the unaffected limb from the distance between the summit of the femoral
head and the mid-level of the lesser trochanter of the affected limb
cThe nature of FO was classified as follows: FO that was consistent from the initial presentation to the last follow-up (Type A); FO that was not observed at the ini-
tial presentation but that developed during treatment and remained consistent until the last follow-up (Type B); FO that was observed at the initial presentation
but that was not apparent during follow-up (Type C); and FO that developed after the initial presentation and subsequently resolved (Type D)
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distant from the osteotomy [17]. In fact, 10 of the 11 pa-
tients (90.9 %) who initially presented without FO but
who later developed it (Type B and Type D patients)
had undergone DO; most of these patients (9/10) under-
went only one round of DO. Seven of these 10 patients
exhibited FO initiated during the tibial lengthening
process. However, DO did not always stimulate FO. In
four patients, the initial FO was no longer apparent dur-
ing follow-up (Type C). All but one of these patients
underwent several rounds of DO and regained >35 % of
the tibial length after distraction. We inferred that re-
peated and extensive limb lengthening may induce
growth disturbance in these patients, a conclusion that
was concurrent with a previous report on lengthening in
children with achondroplasia [19]. Compressive forces
across the physis or damage to the blood supply around
the physis have been proposed as the cause(s) of the
growth disturbance [19]. We suggest that undergoing
tibial lengthening only once may stimulate FO, whereas
repeated and extensive lengthening might inhibit FO.
Neurofibromatosis appears to be another contribu-
tor to FO in CPT. In this study, an increased femoral
neck-shaft angle of the affected limb was significantly
associated with FO. In addition, the tendency towards
increased femoral neck-shaft angle, with a resultant
length-gain effect, persisted throughout follow-up, re-
gardless of the extent of the tibial length gain. Des-
pite the absence of a direct association between the
coexistence of NF1 and FO, we postulated that the
increased femoral neck-shaft angle of the affected
limb might have originated from NF1 because over-
growth phenomena and coxa valga are clinical charac-
teristics of neurofibromatosis [1, 2, 16]. In fact, only
one patient, who exhibited FO in the prepseudarthro-
tic stage, concurrently had NF1.
We found that the patterns of FO in our series
were quite different from those previously reported
by Shapiro [16] in neurofibromatosis, which is
closely related to CPT. He reported that the limb
length discrepancy in most children with neuro-
fibromatosis showed a linear pattern of progression.
However, the upward slope-plateau pattern (modified
Shapiro Type 3) was most common in our study
population, and only one patient showed an upward
linear slope growth-stimulated pattern (modified
Shapiro Type 1). The upward slope-deceleration pat-
tern, the upward slope-plateau-upward slope pattern,
and the upward slope-plateau-downward slope pat-
tern were also observed. Five cases could not be
classified according to Shapiro’s developmental pat-
terns. Diverse patterns of FO in our series may have
resulted from complex interactions involving a com-
pensatory response to frank pseudarthrosis, DO
treatment, and neurofibromatosis.
This study has several limitations. First, the measurement
of actual segment length for a tibia with anterolateral bow-
ing is impractical, especially in patients with atrophic-type
CPT; hence, in this study, we measured effective tibial
length [11] instead of actual tibial length. However, the ef-
fective tibial length may be affected by the amount of the
loaded weight; we inferred that this is the reason why the
extent of tibial shortening did not correlate with FO in the
current study. In addition, the method for measuring the
femoral neck-shaft angle may have been influenced by fem-
oral anteversion, which was not precisely addressed. There-
fore, to improve statistical significance, we defined an
increase of ≥10° in the femoral neck-shaft angle of the af-
fected limb to be an increased femoral neck-shaft angle. Fi-
nally, in our series, no specific case exhibited FO initiation
when frank pseudarthrosis was established, although the
development of frank pseudarthrosis noticeably contributed
to FO in the multivariate analysis. These limitations were
inevitable because of the retrospective study design. In fu-
ture studies, a prospective approach should be considered.
Conclusions
Our observations indicate that FO of the affected limb is
frequently encountered in patients with atrophic-type
CPT. A compensatory response to frank pseudarthrosis,
DO treatment, and neurofibromatosis may play a role in
the diverse patterns of FO.
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